Sionna (SION) CLO Jennifer Fitzpatrick Receives RSU Grants & Option Reprice

What Happened

• Jennifer Fitzpatrick, Chief Legal Officer and Head of Program Management at Sionna Therapeutics, received two restricted stock unit (RSU) awards totaling 56,265 RSUs (28,133 time‑based; 28,132 performance‑based) on 2026-09-17. The filing shows $0 cash paid for these awards (typical for RSU grants).
• The filing also reports a 103,140‑share derivative transaction tied to an option repricing effective 2026-09-17: the repriced options are reported as both “acquired” and “disposed” the same day (both $0 reported). The repriced options carry an exercise price of $7.18 per share as of the repricing date.

Key Details

• Transaction date: 2026-09-17; Form 4 filed 2026-09-18 (timely filing).
• RSUs: 28,133 time‑based RSUs vesting June 17, 2027 (subject to continued service); 28,132 RSUs vesting upon achievement of a performance milestone (subject to continued service).
• Options: 103,140 options were repriced; new exercise price = $7.18 per share. Retention period runs through the earliest of (i) 18 months from repricing (until 3/17/2028), (ii) a sale event, or (iii) certain qualifying terminations. If exercised before the retention period ends, the exercise price may revert to the original price (per footnote).
• Exemption: Board-approved repricing; transactions reported as exempt under Rule 16b-6(d) and Rule 16b-3.
• Cash/value reported: $0 for the RSU grants and the derivative entries (no open‑market buy or sale).
• Shares owned after transaction: not specified in the information provided in this summary.

Context

• RSUs are contingent rights to receive shares on vesting; they do not require an immediate cash outlay by the insider and are not the same as an open‑market purchase (less direct signal of immediate insider buying).
• The derivative entries reflect an option repricing/cancellation and reissuance process rather than a straightforward sale or cash exercise; the filing notes special retention and reversion rules tied to early exercise.
• These movements are routine compensation actions and corporate equity adjustments; they should be interpreted as grants and plan changes, not as open‑market insider buying or selling.